Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

Sponsor
Bristol-Myers Squibb
Study ID
NCT06421311
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • nivolumab — DRUG
    According to approved product label (France)

Study Details

This study will estimate the real-world effectiveness of adjuvant nivolumab therapy in adult participants with muscle invasive urothelial carcinoma (MIUC) in France.

Key Dates

Start date
Jul 30, 2024
Status verified
Jun 2025
Primary completion
Apr 4, 2025
Completion
Apr 4, 2025

Study Design

Enrollment
176 participants (actual)

Arms

  • Arm: Participants with muscle invasive urothelial carcinoma receiving nivolumab

Primary Outcome Measure

Disease-free survival (DFS) of participants [ Time Frame: At months 3, 6, 9, 12, 18, 24, 30, 26, 48 and 60 ]

Related Studies